174 related articles for article (PubMed ID: 8707752)
1. Lack of interaction between valaciclovir, the L-valyl ester of acyclovir, and Maalox antacid.
de Bony F; Bidault R; Peck R; Posner J
J Antimicrob Chemother; 1996 Feb; 37(2):383-7. PubMed ID: 8707752
[TBL] [Abstract][Full Text] [Related]
2. Lack of pharmacokinetic interaction between the oral anti-influenza neuraminidase inhibitor prodrug oseltamivir and antacids.
Snell P; Oo C; Dorr A; Barrett J
Br J Clin Pharmacol; 2002 Oct; 54(4):372-7. PubMed ID: 12392584
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics and safety of multiple-dose valaciclovir in geriatric volunteers with and without concomitant diuretic therapy.
Wang LH; Schultz M; Weller S; Smiley ML; Blum MR
Antimicrob Agents Chemother; 1996 Jan; 40(1):80-5. PubMed ID: 8787884
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of the acyclovir pro-drug valaciclovir after escalating single- and multiple-dose administration to normal volunteers.
Weller S; Blum MR; Doucette M; Burnette T; Cederberg DM; de Miranda P; Smiley ML
Clin Pharmacol Ther; 1993 Dec; 54(6):595-605. PubMed ID: 8275615
[TBL] [Abstract][Full Text] [Related]
5. Phase I trial of valaciclovir, the L-valyl ester of acyclovir, in patients with advanced human immunodeficiency virus disease.
Jacobson MA; Gallant J; Wang LH; Coakley D; Weller S; Gary D; Squires L; Smiley ML; Blum MR; Feinberg J
Antimicrob Agents Chemother; 1994 Jul; 38(7):1534-40. PubMed ID: 7979285
[TBL] [Abstract][Full Text] [Related]
6. Absolute bioavailability and metabolic disposition of valaciclovir, the L-valyl ester of acyclovir, following oral administration to humans.
Soul-Lawton J; Seaber E; On N; Wootton R; Rolan P; Posner J
Antimicrob Agents Chemother; 1995 Dec; 39(12):2759-64. PubMed ID: 8593015
[TBL] [Abstract][Full Text] [Related]
7. Lack of interaction between valaciclovir, the L-valyl ester of aciclovir, and digoxin.
Soul-Lawton JH; Weatherley BC; Posner J; Layton G; Peck RW
Br J Clin Pharmacol; 1998 Jan; 45(1):87-9. PubMed ID: 9489600
[TBL] [Abstract][Full Text] [Related]
8. Valaciclovir (BW256U87): the L-valyl ester of acyclovir.
Jacobson MA
J Med Virol; 1993; Suppl 1():150-3. PubMed ID: 8245883
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of the influence of antacids and H2 antagonists on the absorption of moxifloxacin after oral administration of a 400mg dose to healthy volunteers.
Stass H; Böttcher MF; Ochmann K
Clin Pharmacokinet; 2001; 40 Suppl 1():39-48. PubMed ID: 11352441
[TBL] [Abstract][Full Text] [Related]
10. Influence of the antacid Maalox and the H2-antagonist cimetidine on the pharmacokinetics of cerivastatin.
Mück W; Ritter W; Dietrich H; Frey R; Kuhlmann J
Int J Clin Pharmacol Ther; 1997 Jun; 35(6):261-4. PubMed ID: 9208343
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of pharmacokinetic interactions after oral administration of mycophenolate mofetil and valaciclovir or aciclovir to healthy subjects.
Gimenez F; Foeillet E; Bourdon O; Weller S; Garret C; Bidault R; Singlas E
Clin Pharmacokinet; 2004; 43(10):685-92. PubMed ID: 15244498
[TBL] [Abstract][Full Text] [Related]
12. Bioavailability of aciclovir after oral administration of aciclovir and its prodrug valaciclovir to patients with leukopenia after chemotherapy.
Steingrimsdottir H; Gruber A; Palm C; Grimfors G; Kalin M; Eksborg S
Antimicrob Agents Chemother; 2000 Jan; 44(1):207-9. PubMed ID: 10602752
[TBL] [Abstract][Full Text] [Related]
13. Valacyclovir: a review of its antiviral activity, pharmacokinetic properties, and clinical efficacy.
Beutner KR
Antiviral Res; 1995 Dec; 28(4):281-90. PubMed ID: 8669888
[TBL] [Abstract][Full Text] [Related]
14. Interaction of meloxicam with cimetidine, Maalox, or aspirin.
Busch U; Heinzel G; Narjes H; Nehmiz G
J Clin Pharmacol; 1996 Jan; 36(1):79-84. PubMed ID: 8932547
[TBL] [Abstract][Full Text] [Related]
15. Acyclovir-valaciclovir equilibrium between peritoneal fluid and plasma.
Stathoulopoulou F; Dhillon S; Stathakis C; Stamatiadis D
Perit Dial Int; 2001; 21(6):614-7. PubMed ID: 11783773
[No Abstract] [Full Text] [Related]
16. Lack of pharmacokinetic interaction between linezolid and antacid in healthy volunteers.
Grunder G; Zysset-Aschmann Y; Vollenweider F; Maier T; Krähenbühl S; Drewe J
Antimicrob Agents Chemother; 2006 Jan; 50(1):68-72. PubMed ID: 16377669
[TBL] [Abstract][Full Text] [Related]
17. Effect of Maalox on the bioavailability of oral gemifloxacin in healthy volunteers.
Allen A; Vousden M; Porter A; Lewis A
Chemotherapy; 1999; 45(6):504-11. PubMed ID: 10567782
[TBL] [Abstract][Full Text] [Related]
18. Acyclovir concentrations in human breast milk after valaciclovir administration.
Sheffield JS; Fish DN; Hollier LM; Cadematori S; Nobles BJ; Wendel GD
Am J Obstet Gynecol; 2002 Jan; 186(1):100-2. PubMed ID: 11810093
[TBL] [Abstract][Full Text] [Related]
19. Review of research leading to new anti-herpesvirus agents in clinical development: valaciclovir hydrochloride (256U, the L-valyl ester of acyclovir) and 882C, a specific agent for varicella zoster virus.
Purifoy DJ; Beauchamp LM; de Miranda P; Ertl P; Lacey S; Roberts G; Rahim SG; Darby G; Krenitsky TA; Powell KL
J Med Virol; 1993; Suppl 1():139-45. PubMed ID: 8245881
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetic interaction between flurbiprofen and antacids in healthy volunteers.
Caillé G; du Souich P; Vézina M; Pollock SR; Stalker DJ
Biopharm Drug Dispos; 1989; 10(6):607-15. PubMed ID: 2611360
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]